Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07188558 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
A Phase 3 study of Non-Hodgkin Lymphoma and Lymphoma, B-Cell, sponsored by Lyell Immunopharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT07188558 is a Phase 3 study of Non-Hodgkin Lymphoma and Lymphoma, B-Cell that is actively recruiting participants, run by Lyell Immunopharma. The registered enrollment target is 400 participants, above the 148-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (170% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT07188558, a Phase 3 study of Non-Hodgkin Lymphoma and Lymphoma, B-Cell, is actively recruiting participants, sponsored by Lyell Immunopharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Conditions Studied
Interventions
- BIOLOGICAL rondecabtagene autoleucel
- BIOLOGICAL axicabtagene ciloleucel
- BIOLOGICAL lisocabtagene maraleucel
Study Locations (20)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Honor Health - Scottsdale
- Mayo Clinic Arizona - Scottsdale
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California, Los Angeles (UCLA) - Los Angeles
- University of California, Irvine - Orange
Florida
- Mayo Clinic Florida - Jacksonville
- AdventHealth - Orlando
- Moffitt Cancer Center - Tampa
Colorado
- University of Colorado - Aurora
- Colorado Blood Cancer Institute - Denver
Illinois
- Northwestern - Chicago
- University of Chicago - Chicago
Kentucky
- University of Kentucky - Lexington
- University of Louisville Health - Louisville
Arkansas
- University of Arkansas - Little Rock
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2032-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07188558
The ClinicalTrials.gov registry entry for NCT07188558 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 148-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (170% higher). The listed sponsor is Lyell Immunopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which rondecabtagene autoleucel is the first listed.
NCT07188558 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07188558 about?
NCT07188558 is a clinical study titled "A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy". This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
What is the current status of trial NCT07188558?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2026-01-12. Estimated completion is 2032-01.
What conditions does trial NCT07188558 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Lymphoma, B-Cell, Large B-cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT07188558?
The interventions under investigation include: rondecabtagene autoleucel (BIOLOGICAL), axicabtagene ciloleucel (BIOLOGICAL), lisocabtagene maraleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT07188558?
This trial is sponsored by Lyell Immunopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07188558 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
RECRUITING · Phase 3
-
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.